UNSPSC 51171926: Sevelamer

This classification denotes a polyamine compound with the molecular formula (C9H18N2O)n.(C3H7N)n, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 941N5DUU5C, chemically known as 2-propen-1-amine polymer with (chloromethyl)oxirane, hydrochloride but generally known as sevelamer, which bears US NIH Compound Identifier 159247. European Medicines Agency schedules Sevelamer in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04381MIG. The term SEVELAMER is an International Non-Proprietary Name.

UNSPSC 51171926 Sevelamer, a Commodity code, represents pharmaceutical products procured by state and local health agencies, corrections departments, and cooperative purchasing alliances. Recent state and local opportunities show demand for both branded and generic pharmaceuticals supplied through established wholesale channels and direct-to-manufacturer arrangements. The mix of issuing bodies spans state health and human services commissions, county corrections departments, and multistate cooperative purchasing organizations that aggregate demand across participating jurisdictions. Work solicited under this code includes generic multi-source pharmaceuticals and over-the-counter products meeting FDA and cGMP requirements, direct-to-manufacturer prescription fulfillment programs, and specimen collection and drug testing services incorporating pharmaceutical screening and confirmation protocols.

Recent activity clusters in Texas and Minnesota. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with responses due March 26, 2026; the contract term is two years effective July 1, 2026, with optional extensions, and vendors must maintain relationships with AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC as authorized wholesalers. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program without formal award values or timelines specified at the RFI stage. Collin County Community Supervision and Corrections Department issued RFP 2026-327 on July 9, 2026, for offender specimen collection and drug testing services with an estimated contract value of $600,000 and a response deadline of July 23, 2026; the two-year term commences September 1, 2026, with three optional one-year renewal periods, and encompasses immunoassay screening with LC/MS/MS or GC/MS confirmation serving approximately 25,031 annual tests across two collection sites in Plano and McKinney.